
Saturday, March 23, 2019 1:05:18 PM
If it's true that they are talking amongst themselves about the possibility of a buyout, then I would think those rumors must have at least some possibility of coming true.
Why? If your a drug rep hearing rumors of a possible takeover, the first question you might ask is, "What's going to happen to me? Will I be let go? Will the new company keep me on? Should I be looking for another job now? Where will the kids go to school?
Wouldn't that distract from your focus on selling? Wouldn't that maybe make you want to look elsewhere for a job to get ahead of the curve?
JT wouldn't want that, right?
So if there was no buyout being considered, at least not over his dead body, I would think JT would want to put the rumors to rest by announcing inside the company that there is absolutely no chance of a buyout, so that his salesforce could focus on selling drugs instead of their homes.
On the other hand, maybe JT has done just that, announcing there is absolutely no buyout possibility. I suppose some reps might still believe the company could be sold. But seems for the most part there would be some way JT could find to put those rumors to bed and quell the talk if there really is nothing at all to them.
Recent AMRN News
- Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering • GlobeNewswire Inc. • 02/27/2025 02:00:00 PM
- Amarin Receives National Reimbursement for VAZKEPA® in Austria • GlobeNewswire Inc. • 02/25/2025 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025 • GlobeNewswire Inc. • 02/19/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2024 09:15:07 PM
- Amarin Receives National Reimbursement for VAZKEPA® in Italy • GlobeNewswire Inc. • 12/16/2024 12:00:00 PM
- Amarin Appoints Peter Fishman Chief Financial Officer • GlobeNewswire Inc. • 12/13/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2024 09:49:38 PM
- Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual • GlobeNewswire Inc. • 11/11/2024 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 08:42:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/30/2024 08:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 08:10:08 PM
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 10/30/2024 08:05:00 PM
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
VAYK Proposes 100 million Buyback through Private Repurchases • VAYK • Feb 28, 2025 9:00 AM
ConnectM Eliminates an Additional $1.9 Million of Debt • CNTM • Feb 27, 2025 4:01 PM
Consumer Automotive Finance, Inc. Announces Nationwide Teleconference as It Transitions to Fifty 1 Labs, Inc. • CAFI • Feb 27, 2025 9:00 AM
VPR Brands Secures Settlement Agreement With POP Vapor, Reinforcing Commitment to Intellectual Property Protection • VPRB • Feb 27, 2025 8:49 AM
Wytec Begins Sales of Its Multi-Government AI Threat Detection Sensor Technology • WYTC • Feb 27, 2025 7:05 AM
VAYK Issues Clerical Correction to Feb 18 News Regarding Shareholder Premium • VAYK • Feb 26, 2025 10:32 AM